Zenas BioPharma (ZBIO) Change in Account Payables (2023 - 2026)

Zenas BioPharma's Change in Account Payables history runs 4 years deep, the most recent figure standing at $1.8 million for Q1 2026.

• On a quarterly basis, Change in Account Payables fell 37.72% year-over-year to $1.8 million in Q1 2026; TTM through Mar 2026 was -$11.1 million, a 199.24% decrease from a year earlier, with the FY2025 full-year figure at -$10.0 million, down 185.55% from the prior year.
• Change in Account Payables rose to $1.8 million in Q1 2026 per ZBIO's latest filing, from $1.1 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $5.4 million in Q4 2024 and bottomed at -$12.1 million in Q2 2025.
• The 4-year median for Change in Account Payables is $2.3 million (2025), against an average of $661200.0.
• Across the five-year window, Change in Account Payables soared 73.75% in 2024 and plunged 2418.12% in 2025, its largest moves.
• Year by year, Change in Account Payables stood at $3.1 million in 2023, then surged by 73.75% to $5.4 million in 2024, then slumped by 79.41% to $1.1 million in 2025, then jumped by 60.84% to $1.8 million in 2026.
• Per Business Quant, the three latest ZBIO Change in Account Payables figures stand at $1.8 million (Q1 2026), $1.1 million (Q4 2025), and -$2.0 million (Q3 2025).